Pipeline

Pipeline

Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. The company also plans to use its proprietary protein replacement therapy platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.